Literature DB >> 10942534

BRCA2-null embryonic survival is prolonged on the BALB/c genetic background.

L M Bennett1, K A McAllister, P E Blackshear, J Malphurs, G Goulding, N K Collins, T Ward, D O Bunch, E M Eddy, B J Davis, R W Wiseman.   

Abstract

Women who inherit mutations in the BRCA2 cancer susceptibility gene have an 85% chance of developing breast cancer. The function of the BRCA2 gene remains elusive, but there is evidence to support its role in transcriptional transactivation, tumor suppression, and the maintenance of genomic integrity. Individuals with identical BRCA2 mutations display a different distribution of cancers, suggesting that there are low-penetrance genes that can modify disease outcome. We hypothesized that genetic background could influence embryonic survival of a Brca2 mutation in mice. Brca2-null embryos with a 129/SvEv genetic background (129(B2-/-)) died before embryonic day 8. 5. Transfer of this Brca2 mutation onto the BALB/cJ genetic background (BALB/c(B2-/-)) extended survival to embryonic day 10.5. These results indicate that the BALB/c background harbors genetic modifiers that can prolong Brca2-null embryonic survival. The extended survival of BALB/c(B2-/-) embryos enabled us to ask whether transcriptional regulation of the Brca1 and Brca2 genes is interdependent. The interdependence of Brca1 and Brca2 was evaluated by studying Brca2 gene expression in BALB/c(B1-/-) embryos and Brca1 gene expression in BALB/c(B2-/-) embryos. Nonisotopic in situ hybridization demonstrated that Brca2 transcript levels were comparable in BALB/c(B1-/-) embryos and wild-type littermates. Likewise, reverse transcriptase-polymerase chain reactions confirmed Brca1 mRNA expression in embryonic day 8.5 BALB/c(B2-/-) embryos that was comparable to Brca2-heterozygous littermates. Thus, the Brca1 and Brca2 transcripts are expressed independently of one another in Brca1- and Brca2-null embryos. Mol. Carcinog. 28:174-183, 2000. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10942534     DOI: 10.1002/1098-2744(200007)28:3<174::aid-mc6>3.0.co;2-c

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  6 in total

Review 1.  Chimeric mice with humanized liver: tools for the study of drug metabolism, excretion, and toxicity.

Authors:  Stephen C Strom; Julio Davila; Markus Grompe
Journal:  Methods Mol Biol       Date:  2010

2.  High efficiency of BRCA1 knockout using rAAV-mediated gene targeting: developing a pig model for breast cancer.

Authors:  Yonglun Luo; Juan Li; Ying Liu; Lin Lin; Yutao Du; Shengting Li; Huanming Yang; Gábor Vajta; Henrik Callesen; Lars Bolund; Charlotte Brandt Sørensen
Journal:  Transgenic Res       Date:  2010-12-22       Impact factor: 2.788

3.  CYP1A1 and CYP1A2 expression: comparing 'humanized' mouse lines and wild-type mice; comparing human and mouse hepatoma-derived cell lines.

Authors:  Shigeyuki Uno; Kaori Endo; Yuji Ishida; Chise Tateno; Makoto Makishima; Katsutoshi Yoshizato; Daniel W Nebert
Journal:  Toxicol Appl Pharmacol       Date:  2009-03-10       Impact factor: 4.219

4.  Brca2 deficiency leads to T cell loss and immune dysfunction.

Authors:  Jun-Hyeon Jeong; Areum Jo; Pilgu Park; Hyunsook Lee; Hae-Ock Lee
Journal:  Mol Cells       Date:  2015-02-04       Impact factor: 5.034

Review 5.  Mouse Models for Deciphering the Impact of Homologous Recombination on Tumorigenesis.

Authors:  Gabriel Matos-Rodrigues; Emmanuelle Martini; Bernard S Lopez
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639

6.  Nucks1 synergizes with Trp53 to promote radiation lymphomagenesis in mice.

Authors:  Yangbo Yue; Stanley G Leung; Yueyong Liu; Yurong Huang; Kirsten Grundt; Anne-Carine Østvold; Kuang-Yu Jen; David Schild; Jian-Hua Mao; Claudia Wiese
Journal:  Oncotarget       Date:  2016-09-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.